Skip to main content
. 2024 Nov 17;9:222. doi: 10.1038/s41541-024-01014-8

Table 1.

Summary of the effects of CpG 1018 and AddaVax on the immunogenicity of different mHA vaccine platforms

Unadjuvanted CpG 1018-adjuvanted AddaVax-adjuvanted
mHA WIV Vaccine High immunogenicity with Th1-biased immune response Limited increase in in vivo cross-protection Decrease in serum passive transfer cross-protection
mHA split vaccine Moderate immunogenicity with Th2-biased immune response Increase in in vivo cross-protection Increase in serum passive transfer cross-protection